SpyGlass Pharma (SGP) Total Liabilities (2024 - 2026)
SpyGlass Pharma (SGP) posted quarterly Total Liabilities of $10.2 million for Q4 2025, down 9.6% year-over-year from $11.2 million in Q4 2024, and down 9.6% quarter-over-quarter from $11.2 million in Q4 2024.
Powered by 
Analysis
SpyGlass Pharma (SGP) Total Liabilities (2024 - 2026) Analysis & Trends
SpyGlass Pharma (SGP) has reported Total Liabilities for 2 consecutive years, with $10.2 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Total Liabilities fell 9.6% year-over-year to $10.2 million; the TTM figure through Dec 2025 stood at $10.2 million (down 9.6% YoY), while the FY2025 annual figure was $10.2 million, down 9.6% from the prior year.
- Total Liabilities fell to $10.2 million in Q4 2025 per SGP's latest filing, from $11.2 million in the prior quarter.
- Across five years, Total Liabilities topped out at $11.2 million in Q4 2024 and bottomed at $10.2 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 4.20 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 1.72 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 4.00 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 4.20 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 10.03 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.35 Bn |
| 10 | SpyGlass Pharma | 973.76 Mn | 973.76 Mn | - | 11.07 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 11.07 Mn |
| Dec 31, 2025 | 10.17 Mn |
| Jun 30, 2025 | 78.38 Mn |
| Dec 31, 2024 | 11.25 Mn |